Literature DB >> 12878511

Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.

Jenny Dahl Knudsen1, Inga Odenholt, Helga Erlendsdottir, Magnus Gottfredsson, Otto Cars, Niels Frimodt-Møller, Frank Espersen, Karl G Kristinsson, Sigurdur Gudmundsson.   

Abstract

Pharmacokinetic (PK) and pharmacodynamic (PD) properties for the selection of resistant pneumococci were studied by using three strains of the same serotype (6B) for mixed-culture infection in time-kill experiments in vitro and in three different animal models, the mouse peritonitis, the mouse thigh, and the rabbit tissue cage models. Treatment regimens with penicillin were designed to give a wide range of T(>MIC)s, the amounts of time for which the drug concentrations in serum were above the MIC. The mixed culture of the three pneumococcal strains, 10(7) CFU of strain A (MIC of penicillin, 0.016 micro g/ml; erythromycin resistant)/ml, 10(6) CFU of strain B (MIC of penicillin, 0.25 micro g/ml)/ml, and 10(5) CFU of strain C (MIC of penicillin, 4 micro g/ml)/ml, was used in the two mouse models, and a mixture of 10(5) CFU of strain A/ml, 10(4) CFU of strain B/ml, and 10(3) CFU of strain C/ml was used in the rabbit tissue cage model. During the different treatment regimens, the differences in numbers of CFU between treated and control animals were calculated to measure the efficacies of the regimens. Selective media with erythromycin or different penicillin concentrations were used to quantify the strains separately. The efficacies of penicillin in vitro were similar when individual strains or mixed cultures were studied. The eradication of the bacteria, independent of the susceptibility of the strain or strains or the presence of the strains in a mixture or on their own, followed the well-known PK and PD rules for treatment with beta-lactams: a maximum efficacy was seen when the T(>MIC) was >40 to 50% of the observation time and the ratio of the maximum concentration of the drug in serum to the MIC was >10. It was possible in all three models to select for the less-susceptible strains by using insufficient treatments. In the rabbit tissue cage model, a regrowth of pneumococci was observed; in the mouse thigh model, the ratio between the different strains changed in favor of the less-susceptible strains; and in the mouse peritonitis model, the susceptible strain disappeared and was overgrown by the less-susceptible strains. These findings with the experimental infection models confirm the importance of eradicating all the bacteria taking part in the infectious process in order to avoid selection of resistant clones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878511      PMCID: PMC166083          DOI: 10.1128/AAC.47.8.2499-2506.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Multidrug-resistant Streptococcus pneumoniae: An opportunity to further understand pneumococcal ecology and to better predict intervention outcomes.

Authors:  A J Leach
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

Review 2.  Antibiotic-selective environments.

Authors:  F Baquero; M C Negri; M I Morosini; J Blázquez
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

Review 3.  Selective compartments for resistant microorganisms in antibiotic gradients.

Authors:  F Baquero; M C Negri
Journal:  Bioessays       Date:  1997-08       Impact factor: 4.345

Review 4.  Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

Authors:  R Dagan; K P Klugman; W A Craig; F Baquero
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

5.  Pharmacodynamics of penicillin are unaffected by bacterial growth phases of Streptococcus pneumoniae in the mouse peritonitis model.

Authors:  J D Knudsen; N Frimodt-Møller; F Espersen
Journal:  J Antimicrob Chemother       Date:  1998-04       Impact factor: 5.790

6.  The pneumococcus at the gates.

Authors:  A Tomasz
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

Review 7.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

8.  Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae.

Authors:  D Guillemot; C Carbon; B Balkau; P Geslin; H Lecoeur; F Vauzelle-Kervroëdan; G Bouvenot; E Eschwége
Journal:  JAMA       Date:  1998-02-04       Impact factor: 56.272

9.  A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae.

Authors:  A J Leach; T M Shelby-James; M Mayo; M Gratten; A C Laming; B J Currie; J D Mathews
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

10.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

View more
  14 in total

Review 1.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Bacteriophage orphan DNA methyltransferases: insights from their bacterial origin, function, and occurrence.

Authors:  James Murphy; Jennifer Mahony; Stuart Ainsworth; Arjen Nauta; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2013-10-11       Impact factor: 4.792

5.  Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Authors:  Peter Ankomah; Bruce R Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

6.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

7.  Optimal drug synergy in antimicrobial treatments.

Authors:  Joseph Peter Torella; Remy Chait; Roy Kishony
Journal:  PLoS Comput Biol       Date:  2010-06-03       Impact factor: 4.475

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial.

Authors:  Lorenzo Aguilar; María-José Giménez; José Barberán
Journal:  Infect Drug Resist       Date:  2010-06-18       Impact factor: 4.003

10.  Efficacy of high doses of oral penicillin versus amoxicillin in the treatment of adults with non-severe pneumonia attended in the community: study protocol for a randomised controlled trial.

Authors:  Carl Llor; Javier Arranz; Rosa Morros; Anna García-Sangenís; Helena Pera; Joan Llobera; Mireia Guillén-Solà; Eugenia Carandell; Jesús Ortega; Silvia Hernández; Marc Miravitlles
Journal:  BMC Fam Pract       Date:  2013-04-17       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.